03678nam a2200301 a 4500003000900000005001700009008004100026040002800067041001800095082000800113100003800121245021000159246020100369264000900570300005400579336002200633337002500655338002300680502009300703504003300796520234000829530002203169546005403191650001803245653002403263700004403287700004503331EG-GiCUC20260516142557.0220228s2021    ua dh  frm    000 0 eng d  aEG-GiCUCcEG-GiCUCbeng0 aengbengbara04a5400 aManar Hesham Fouad,epreparation.10aImpact of notch1 signaling pathway on clinical course of pediatric t-cell acute lymphoblastic leukemia / cby Manar Hesham Fouad ; Supervised Prof.Dr.Mahfouz Ali Abdelaziz , Prof.Dr.Nashwa Nagy Elkhazragy.15aتأثير مسار نوتش على خط السير الاكلينكي لمرض سرطان الدم اللميفاوي الحاد من نوع الخلية التائية فى الأطفال  0c2022  a216 Pages : bcharts , facsimiles ; c30 cm+ eCD  atext2rda content  aUnmediated2rdamedia  avolume2rdacarrier  aThesis (M.Sc.) - Cairo University - Faculty of Science - Department of Organic Chemistry  aBibliography: pages 140-227. 3aAcute Lymphoblastic Leukemia (ALL) represents the most commonly diagnosed cancer in children. T-cell Acute Lymphoblastic Leukemia (T-cell ALL) accounts for around 10-15% of pediatric ALL cases and 25% of adult cases. Constitutive activation of Notch signaling pathway takes place, as a result of NOTCH1 activating mutations, in over 60 % of T-ALL cases. Despite the remarkable improvement that the world has witnessed over the last half-century in the prognosis of ALL, relapse is still a major challenge. Also, the increasing percentage of patients suffering from treatment-related toxicities or chemotherapeutic resistance and recurrence has indicated the inaccuracy of the currently used risk allocation schemes, which consequently explains the necessity of a more reliable assessment approach of the leukemic status. Consequently, a deeper understanding of T-ALL biology at the molecular level is urgently needed to facilitate the identification of novel diagnostic and prognostic biomarkers and therapeutic targets that can ultimately enable early detection, targeted therapy with minimal side effects, and hence a better prognosis. More attention has been paid towards investigating the direct and indirect regulatory roles that NOTCH1 plays in order to promote leukemogenesis. The oncogenic microRNA miR-21 has been implicated in several hematological malignancies and solid tumors. Its oncogenic role in T-ALL is being exhibited through targeting the tumorsuppressive programmed cell death protein 4 (PCDP4). Its aberrant expression has also been associated with a poor prognosis. On the other hand, miR-193b-3p, or miR-193b, is a wellcharacterized tumor-suppressive microRNA that is usually downregulated in a wide range of cancers. In T{u2010} cell acute lymphoblastic leukemia, miR{u2010} 193b{u2010} 3p was also found to be repressed, and its repression was negatively associated with the proto{u2010} oncogene MYB expression. Its downregulation was also found to be associated with unfavorable prognostic features. Although the Notch-regulated long non-coding RNA, LUNAR1, has been demonstrated to be among the most prominently dysregulated lncRNAs in T-ALL cases, the association of its expression levels in the peripheral blood of patients with the clinicopathological features and/or prognosis has not been assessed yet  aIssued also as CD  aText in English and abstract in Arabic & English. 0aBioechnology  1aALLaMiR-21aNOTCH10 aMahfouz Ali Abdelaziz ethesis advisor.0 aNashwa Nagy Elkhazragy ethesis advisor.